EBNK-001 (Not yet branded)

Other Medications

US Experimental IV 1 Clinical Trials
Tumor cells via NK cell cytotoxicity IL-15 receptor

Description

EBNK-001 is an allogeneic natural killer (NK) cell therapy designed for treatment of advanced solid tumors including colorectal cancer. This cellular immunotherapy utilizes donor-derived NK cells that are administered in combination with low-dose interleukin-15 (IL-15) to enhance anti-tumor activity. The therapy may also be combined with pembrolizumab, a PD-1 checkpoint inhibitor, to provide synergistic immune system activation against cancer cells.

Mechanism of Action

EBNK-001 works by infusing allogeneic NK cells that recognize and directly kill cancer cells through cytotoxic mechanisms including perforin and granzyme release. The co-administered IL-15 serves as a growth factor that enhances NK cell survival, proliferation, and cytotoxic function within the tumor microenvironment.

Molecular Targets

Side Effects

Cytokine release syndrome Fever Chills Fatigue Nausea Infusion-related reactions Lymphopenia Elevated liver enzymes

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07410676 Phase 1
Recruiting
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
China

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
AdministrationIV
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Alt-803
Other Medications
2 trials
N-803
Other Medications
2 trials
IL-15
Other Medications
1 trials
Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.